261 related articles for article (PubMed ID: 33191524)
1. Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome.
Gong C; Xiao Q; Li Y; Gu Y; Zhang J; Wang L; Cao J; Tao Z; Zhao Y; Xie Y; Hu X; Wang B
Oncologist; 2021 Apr; 26(4):e580-e587. PubMed ID: 33191524
[TBL] [Abstract][Full Text] [Related]
2. Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma.
Penttilä P; Donskov F; Rautiola J; Peltola K; Laukka M; Bono P
Eur J Cancer; 2017 Aug; 81():9-16. PubMed ID: 28586749
[TBL] [Abstract][Full Text] [Related]
3. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach.
Nishino M; Brais LK; Brooks NV; Hatabu H; Kulke MH; Ramaiya NH
Eur J Cancer; 2016 Jan; 53():163-70. PubMed ID: 26760924
[TBL] [Abstract][Full Text] [Related]
4. Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm.
Nishino M; Boswell EN; Hatabu H; Ghobrial IM; Ramaiya NH
Oncologist; 2015 Sep; 20(9):1077-83. PubMed ID: 26205737
[TBL] [Abstract][Full Text] [Related]
5. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001).
White DA; Schwartz LH; Dimitrijevic S; Scala LD; Hayes W; Gross SH
J Thorac Oncol; 2009 Nov; 4(11):1357-63. PubMed ID: 19745764
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
[TBL] [Abstract][Full Text] [Related]
7. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
[TBL] [Abstract][Full Text] [Related]
8. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome.
Dabydeen DA; Jagannathan JP; Ramaiya N; Krajewski K; Schutz FA; Cho DC; Pedrosa I; Choueiri TK
Eur J Cancer; 2012 Jul; 48(10):1519-24. PubMed ID: 22483544
[TBL] [Abstract][Full Text] [Related]
9. Phase I Trial of Everolimus and Capecitabine in Metastatic HER2
Vidal GA; Chen M; Sheth S; Svahn T; Guardino E
Clin Breast Cancer; 2017 Oct; 17(6):418-426. PubMed ID: 28385537
[TBL] [Abstract][Full Text] [Related]
10. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
11. Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer.
Fukudo M; Ishibashi K; Kitada M
Invest New Drugs; 2021 Dec; 39(6):1707-1715. PubMed ID: 34041638
[TBL] [Abstract][Full Text] [Related]
12. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
O'Shaughnessy J; Thaddeus Beck J; Royce M
Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Pascual T; Apellániz-Ruiz M; Pernaut C; Cueto-Felgueroso C; Villalba P; Álvarez C; Manso L; Inglada-Pérez L; Robledo M; Rodríguez-Antona C; Ciruelos E
PLoS One; 2017; 12(7):e0180192. PubMed ID: 28727815
[TBL] [Abstract][Full Text] [Related]
15. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
Toi M; Shao Z; Hurvitz S; Tseng LM; Zhang Q; Shen K; Liu D; Feng J; Xu B; Wang X; Lee KS; Ng TY; Ridolfi A; Noel-Baron F; Ringeisen F; Jiang Z
Breast Cancer Res; 2017 Apr; 19(1):47. PubMed ID: 28399902
[TBL] [Abstract][Full Text] [Related]
17. Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.
Alvarez RH; Bechara RI; Naughton MJ; Adachi JA; Reuben JM
Oncologist; 2018 Jun; 23(6):660-669. PubMed ID: 29487226
[TBL] [Abstract][Full Text] [Related]
18. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
Jones VE; McIntyre KJ; Paul D; Wilks ST; Ondreyco SM; Sedlacek S; Melnyk A; Oommen SP; Wang Y; Peck SR; O'Shaughnessy JA
Oncologist; 2019 Sep; 24(9):1153-1158. PubMed ID: 30833486
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
